Phuturdex › Drugs › Daraxonrasib
Drugs in development · updated 30 October 2026
Daraxonrasib: clinical trials and development status
Other names and codes: Rasonque
As of 30 October 2026 Daraxonrasib is in 12 active clinical trials (recruiting or ongoing, phases I–III) for 28 diseases. The most advanced phase is III.
Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Daraxonrasib and get an email at every change or safety alert.
Sign in free →Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Pancreatic neoplasm | III | 8 | NCT07252232 |
| Non-small-cell lung carcinoma | III | 4 | NCT06881784 |
| Lung neoplasm | III | 3 | NCT06881784 |
| Colorectal neoplasm | I–II | 3 | NCT06128551 |
| Gastrointestinal neoplasm | II | 2 | NCT07793253 |
| Metastasis | II | 2 | NCT07793253 |
| Appendiceal neoplasm | I–II | 1 | NCT06128551 |
| Biliary tract neoplasm | II | 1 | NCT07793253 |
| Brain Neoplasms | II | 1 | NCT07492680 |
| Bronchial neoplasm | I–II | 1 | NCT06128551 |
| Carcinoma | II | 1 | NCT07793253 |
| Cholangiocarcinoma | II | 1 | NCT07793253 |
| Colonic neoplasm | I–II | 1 | NCT06128551 |
| Endometrial neoplasm | I–II | 1 | NCT06128551 |
| Esophageal neoplasm | I–II | 1 | NCT06128551 |
| Gallbladder neoplasm | II | 1 | NCT07793253 |
| Intestinal neoplasm | I–II | 1 | NCT06128551 |
| Liver neoplasm | II | 1 | NCT07793253 |
| Lung disease | I–II | 1 | NCT06128551 |
| Melanoma | II | 1 | NCT07492680 |
| Neoplasm | I–II | 1 | NCT06128551 |
| Ovarian neoplasm | I–II | 1 | NCT06128551 |
| Pancreatic ductal carcinoma | I–II | 1 | NCT06128551 |
| Rectal neoplasm | I–II | 1 | NCT06128551 |
| Respiratory disease | I–II | 1 | NCT06128551 |
| Respiratory tract neoplasm | I–II | 1 | NCT06128551 |
| Stomach neoplasm | I–II | 1 | NCT06128551 |
| Thoracic Neoplasms | I–II | 1 | NCT06128551 |
Everything on Daraxonrasib
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.